Manivel Rengasamy1, Anna Marsland2, Lora McClain3, Tessa Kovats3, Thomas Walko2, Lisa Pan3, Rebecca B Price4. 1. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: rengasamym@upmc.edu. 2. Department of Psychology, University of Pittsburgh, Pittsburgh, USA. 3. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Psychology, University of Pittsburgh, Pittsburgh, USA.
Abstract
BACKGROUND: Depression has been associated with low-grade elevation of plasma cytokines (e.g. interleukin-6, IL-6; tumor necrosis factor alpha, TNFα) in both cross-sectional and longitudinal studies in adults. Preclinical and clinical studies also suggest that IL-6 and TNFα elevation are associated with anhedonia. However, few studies have examined longitudinal relationships between cytokines and depression/anhedonia in clinically depressed samples, particularly adolescents. METHODS: Thirty-six adolescents with a depressive disorder receiving standard-of-care community treatment were assessed at a baseline and a follow-up timepoint. Self-report and clinical measures of depression and anhedonia, along with plasma IL-6 and TNFα levels, were obtained at both timepoints. Baseline cytokine measures were examined in association with baseline and follow-up clinical measures. On an exploratory basis, change in clinical measures over time was examined in relation to change in cytokine levels over time. RESULTS: Higher baseline TNFα levels predicted higher follow-up depression severity after approximately four months (controlling for baseline depression). Higher baseline TNFα levels also associated positively with baseline anhedonia and predicted higher anhedonia at follow-up (controlling for baseline anhedonia). No association was found between change in clinical measures and change in cytokine levels over time. CONCLUSIONS: Among adolescents receiving standard-of-care community treatment for depression, higher levels of TNFα predicted greater depressive symptoms at 4-month follow-up, suggesting this cytokine may be used to help identify patients in need of more intensive treatment. Elevated TNFα levels were also associated with concurrent and future anhedonia symptoms, suggesting a specific mechanism in which TNFα affects depression trajectories. Future studies should examine the relationships between cytokine levels and depression/anhedonia symptoms at multiple timepoints in larger cohorts of depressed adolescents.
BACKGROUND: Depression has been associated with low-grade elevation of plasma cytokines (e.g. interleukin-6, IL-6; tumor necrosis factor alpha, TNFα) in both cross-sectional and longitudinal studies in adults. Preclinical and clinical studies also suggest that IL-6 and TNFα elevation are associated with anhedonia. However, few studies have examined longitudinal relationships between cytokines and depression/anhedonia in clinically depressed samples, particularly adolescents. METHODS: Thirty-six adolescents with a depressive disorder receiving standard-of-care community treatment were assessed at a baseline and a follow-up timepoint. Self-report and clinical measures of depression and anhedonia, along with plasma IL-6 and TNFα levels, were obtained at both timepoints. Baseline cytokine measures were examined in association with baseline and follow-up clinical measures. On an exploratory basis, change in clinical measures over time was examined in relation to change in cytokine levels over time. RESULTS: Higher baseline TNFα levels predicted higher follow-up depression severity after approximately four months (controlling for baseline depression). Higher baseline TNFα levels also associated positively with baseline anhedonia and predicted higher anhedonia at follow-up (controlling for baseline anhedonia). No association was found between change in clinical measures and change in cytokine levels over time. CONCLUSIONS: Among adolescents receiving standard-of-care community treatment for depression, higher levels of TNFα predicted greater depressive symptoms at 4-month follow-up, suggesting this cytokine may be used to help identify patients in need of more intensive treatment. Elevated TNFα levels were also associated with concurrent and future anhedonia symptoms, suggesting a specific mechanism in which TNFα affects depression trajectories. Future studies should examine the relationships between cytokine levels and depression/anhedonia symptoms at multiple timepoints in larger cohorts of depressed adolescents.
Authors: Daniel P Moriarity; Naoise Mac Giollabhui; Lauren M Ellman; Joshua Klugman; Christopher L Coe; Lyn Y Abramson; Lauren B Alloy Journal: Clin Psychol Sci Date: 2019-03-01
Authors: Yekta Dowlati; Nathan Herrmann; Walter Swardfager; Helena Liu; Lauren Sham; Elyse K Reim; Krista L Lanctôt Journal: Biol Psychiatry Date: 2009-12-16 Impact factor: 13.382
Authors: Floor van Heesch; Jolanda Prins; Gerdien A H Korte-Bouws; Koen G C Westphal; Suzanne Lemstra; Berend Olivier; Aletta D Kraneveld; S Mechiel Korte Journal: Behav Brain Res Date: 2013-07-26 Impact factor: 3.332
Authors: Lisa H Jaycox; Bradley D Stein; Susan Paddock; Jeremy N V Miles; Anita Chandra; Lisa S Meredith; Terri Tanielian; Scot Hickey; M Audrey Burnam Journal: Pediatrics Date: 2009-09-07 Impact factor: 7.124
Authors: Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Yara J Toenders; Liliana Laskaris; Christopher G Davey; Michael Berk; Yuri Milaneschi; Femke Lamers; Brenda W J H Penninx; Lianne Schmaal Journal: Mol Psychiatry Date: 2021-10-11 Impact factor: 15.992
Authors: Mandakh Bekhbat; Zhihao Li; Namrataa D Mehta; Michael T Treadway; Michael J Lucido; Bobbi J Woolwine; Ebrahim Haroon; Andrew H Miller; Jennifer C Felger Journal: Mol Psychiatry Date: 2022-08-04 Impact factor: 13.437
Authors: Dean T Acheson; Meghan Vinograd; Caroline M Nievergelt; Kate A Yurgil; Tyler M Moore; Victoria B Risbrough; Dewleen G Baker Journal: Eur J Psychotraumatol Date: 2022-01-19
Authors: Warren D Taylor; David H Zald; Jennifer C Felger; Seth Christman; Daniel O Claassen; Guillermo Horga; Jeffrey M Miller; Katherine Gifford; Baxter Rogers; Sarah M Szymkowicz; Bret R Rutherford Journal: Mol Psychiatry Date: 2021-08-17 Impact factor: 15.992